GABA Oral Dosage Form with Cellulose Excipients for Food-Independent Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of gamma-aminobutyric acid (GABA) exhibit variable bioavailability when administered with or without food, leading to inconsistent therapeutic effects and potential non-adherence in long-term treatment regimens for diabetes and metabolic syndrome.
Innovation Solution
Development of an oral dosage form comprising GABA with pharmaceutically acceptable excipients, specifically designed to release 100% of the drug within 0.25-5 hours in 0.01 M HCl at 37°C, maintaining comparable bioavailability (+/-30% AUC when administered in both fed and fasting states, using a combination of GABA with 30-50% hydroxypropyl methylcellulose and other excipients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GABA is administered in conventional formulations, then the drug can be delivered orally, but the bioavailability varies significantly when administered with or without food
Solution Approach 1:
The patent modifies the dissolution rate parameter of GABA by formulating it with specific excipients (hydroxypropyl cellulose, hydroxypropyl methylcellulose, or carboxymethyl cellulose) to achieve a controlled release profile. This parameter change ensures that 100% of GABA is released within 0.25-5 hours in acidic conditions, maintaining consistent bioavailability regardless of food intake.
Solution Approach 2:
The invention creates a composite pharmaceutical formulation by combining GABA with cellulose-based excipients. This composite material structure provides sustained release properties and protects GABA from food-induced variability, achieving reliable bioavailability while maintaining oral administration flexibility.
2Speed
If GABA is released quickly in the body, then the drug acts rapidly, but the duration of therapeutic effect is insufficient for metabolic syndrome treatment
Solution Approach 1:
The patent employs dynamic release characteristics by using pH-sensitive cellulose excipients that respond to the gastrointestinal environment. The formulation releases GABA at a controlled rate that adapts to physiological conditions, providing both rapid initial release for quick action and sustained release for extended therapeutic effect duration.
Solution Approach 2:
The invention changes the release rate parameter over time through the use of sustained-release excipients. The formulation is designed to release 100% of GABA within 0.25-5 hours in acidic conditions while maintaining therapeutic levels over an extended period, thus achieving both rapid action and prolonged effect.
3Ease of operation
If conventional GABA formulations are used, then the administration is simple, but the therapeutic effect is inconsistent leading to potential non-adherence
Solution Approach 1:
The patent creates a self-regulating formulation that automatically maintains consistent GABA release regardless of external factors like food intake. The cellulose-based excipients self-adjust to physiological conditions, ensuring reliable bioavailability without requiring patient adherence to complex administration instructions, thus maintaining simplicity while improving consistency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation ensures consistent bioavailability of GABA, allowing for effective treatment or prevention of diabetes and metabolic syndrome regardless of meal intake, thereby improving adherence and therapeutic outcomes.
Implementation Method 1
100% of the GABA is released within 0.25-5 hours in 0.01 M HCl at 37° C. in a USP dissolution apparatus 2
Implementation Method 2
the dosage form comprises 30-50% GABA, 1-35% hydroxypropyl methylcellulose
Data Source
AI summary
The present invention relates to an oral dosage form comprising gamma-aminobutyric acid (GABA) and pharmaceutically acceptable excipients, wherein 100% of the GABA is released within 0.25-5 hours in 0.01 M HCl at 37° C. in a USP dissolution apparatus 2. The invention further relates to specific dosage forms, methods for treatment of autoimmune diseases with the dosage form, as well as use of the dosage form in such methods.